Kiniksa Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $112,214 | $108,631 | $79,858 | $83,395 |
Gross Profit | 62,798 | 66,176 | 48,320 | 56,636 |
EBITDA | -9,658 | 313 | -16,076 | 317 |
EBIT | -10,057 | -117 | -16,542 | 81 |
Net Income | -12,693 | -3,908 | -17,704 | 25,237 |
Net Change In Cash | 112,214 | 108,631 | 79,858 | 83,395 |
Free Cash Flow | -2,236 | 5,168 | 3,903 | 4,269 |
Cash | 97,376 | 99,271 | 141,078 | 107,954 |
Basic Shares | 71,726 | 71,004 | 70,633 | 72,660 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $270,259 | $220,180 | $38,544 | $7,704 |
Gross Profit | 213,735 | 173,214 | 29,444 | -3,805 |
EBITDA | -22,855 | 9,773 | -154,281 | -154,958 |
EBIT | -25,196 | 5,553 | -156,636 | -157,363 |
Net Income | 14,084 | 183,363 | -157,924 | -161,381 |
Net Change In Cash | 270,259 | 220,180 | 38,544 | 7,704 |
Cost of Revenue | 245 | 8,222 | 67,110 | |
Free Cash Flow | 13,171 | 5,702 | -146,713 | -136,815 |
Cash | 107,954 | 122,715 | 122,470 | 114,038 |
Basic Shares | 71,922 | 70,421 | 68,576 | 61,842 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.18 |
2024-06-30 | -$0.06 |
2024-03-31 | -$0.25 |
2023-12-31 | $0.35 |
